P2, N=208, Recruiting, Shandong Provincial Hospital

P=N/A, N=420, Not yet recruiting, Alliance for Clinical Trials in Oncology

Metronomic CAP plus FUL can delay progressive disease (PD) and improve QoL in patients. Although these results are promising, they warrant further validation in larger, multicenter studies due to the limited sample size.

The patient experienced two episodes of PI and PVG with distinct clinical courses. Although the exact cause of the first episode remains unclear, the fatal recurrence suggests that rechallenging with suspected causative agents carries a significant risk, even after dose reduction. While ICI-based chemotherapy for esophageal cancer was highly effective, this case highlights the importance of continuously reassessing the risk-benefit balance during treatment. Discontinuation of ICIs should be considered when serious irAE are suspected.

TBZ reduces tumorigenicity via the regulation of the p53-miR-34a-5p/Snail axis in radioresistant CRC cells and suppression of M2 macrophage polarization, decreasing IL-10 secretion. Our study provides insight into drug repurposing by revealing the mechanism by which TBZ, an FDA-approved drug, reduces tumorigenicity through communication between radioresistant CRC cells and macrophages.

P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

5-Fluorouracil (5-Fu) is a cornerstone chemotherapeutic agent in the treatment of colorectal cancer (CRC)...The circular structure, stability, and subcellular localization of circ-0023919 were confirmed using a combination of approaches, including actinomycin D treatment, RNase R digestion, specific primer PCR amplification, Sanger sequencing and FISH...In this scientific study, circ-0023919 is shown to enhance the resistance of CRC cells to 5-Fu by promoting EMT. Thus, circ-0023919 is considered a potential therapeutic target for CRC treatment.

P=N/A, N=120, Not yet recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Initiation date: Sep 2025 --> Jan 2026

The patient was treated with six cycles of zolbetuximab-CAPOX (zolbetuximab, capecitabine, and oxaliplatin), resulting in complete regression of liver metastases and significant tumor shrinkage. Additionally, transient treatment-related gastritis observed during therapy raises questions about the effects of CLDN18.2 inhibition on gastric mucosal integrity. Further research is warranted to refine patient selection for CLDN18.2-targeted therapy and investigate its broader physiological effects.

We report the case of a 71-year-old male with stage IVB lung adenocarcinoma undergoing maintenance therapy with pembrolizumab and pemetrexed, who presented with an acute confusional state and fever unresponsive to antipyretics. The patient was successfully treated with systemic corticosteroids, resulting in the resolution of fever and neurological symptoms. This case underscores the importance of early recognition and prompt management of CRS in patients receiving immune checkpoint inhibitors, highlighting corticosteroid therapy as an effective treatment strategy.

This regimen was associated with improved DCR, PFS, and OS compared to bevacizumab plus chemotherapy in patients with HER2-negative MBC. These findings suggest that anlotinib may represent a promising therapeutic option for patients for whom ADC drugs are inaccessible or unsuitable; however, further prospective, randomized studies are warranted to confirm.

And the signal of Annexin-V suggested that pemetrexed led oocytes to apoptotic. Overall, our findings revealed that pemetrexed exposure could have detrimental effects on female fertility and result in inferior oocyte quality in female mice.